Cameron, Daniel

CameronDaniel Cameron, MD, MPH
Internist, Epidemiologist
Dr. Daniel Cameron & Associates
Mt. Kisco, NY

“Lyme Disease Clinical Trials, Past, Present & Future”

Dr. Daniel Cameron graduated with degrees in Medicine and Epidemiology from the University of Minnesota followed by residencies at both Beth Israel Medical Center and Mt. Sinai School of Medicine in New York City.

Dr. Cameron is past president of ILADS, the International Lyme and Associated Diseases Society. He has led the field of clinical epidemiology in Lyme disease as an author of the 2004 and 2014 ILADS evidence based treatment guidelines and analytic reviews. He has been treating patients with Lyme disease in his private practice in Mt. Kisco, New York. He regularly communicates by Blog and Facebook at

Conference Lecture Summary

Lyme disease trials continue to frustrate doctors. Short-term successes following treatment for early Lyme disease were followed by reports of chronic manifestations including chronic neurologic Lyme disease, Lyme encephalopathy, Post Treatment Lyme disease and neuropsychiatric Lyme disease. Retreatment trial outcomes have been mixed following early reports of successful treatment for Chronic Neurologic Lyme, Lyme Encephalopathy and Post Lyme Disease. Watchful waiting outcomes trials are similarly mixed. 14.47 % of 76 subjects in one watchful waiting study suffered from Post Treatment Lyme Disease Syndrome (PTLDS) at either six or twelve months despite a one time 3-week course of doxycycline. Eleven percent of individuals in another watchful waiting study suffered from PTLDS for more than 11 years despite timely treatment. Future trial designs will need to adapt to our growing understanding of the complexity of tick borne illnesses.